Search results
Results from the WOW.Com Content Network
Bordetella pertussis is a Gram-negative, aerobic, pathogenic, encapsulated coccobacillus bacterium of the genus Bordetella, and the causative agent of pertussis or whooping cough. Its virulence factors include pertussis toxin , adenylate cyclase toxin , filamentous haemagglutinin , pertactin , fimbria , and tracheal cytotoxin .
Tracheal cytotoxin (TCT) is a 921 dalton glycopeptide released by Bordetella pertussis, [1] Vibrio fischeri (as a symbiosis chemical), [2] and Neisseria gonorrhoeae (among other peptidoglycan-derived cytotoxins it produces). [3]
Adenylate cyclase toxin (CyaA) is released from bacterium Bordetella pertussis by the T1SS (Type 1 secretion system) and released in the host’s respiratory tract in order to suppress its early innate and subsequent adaptive immune defense. [1] CyaA plays a particular role in the early phases of airway colonization.
Bordetella (/ ˌ b ɔːr d ə ˈ t ɛ l ə /) is a genus of small (0.2 – 0.7 μm), Gram-negative, coccobacilli bacteria of the phylum Pseudomonadota. Bordetella species, with the exception of B. petrii, are obligate aerobes, as well as highly fastidious, or difficult to culture.
Whooping cough (/ ˈ h uː p ɪ ŋ / or / ˈ w uː p ɪ ŋ /), also known as pertussis or the 100-day cough, is a highly contagious, vaccine-preventable bacterial disease. [1] [10] Initial symptoms are usually similar to those of the common cold with a runny nose, fever, and mild cough, but these are followed by two or three months of severe coughing fits. [1]
Whooping cough cases are skyrocketing in New York City, according to shocking new data that emerges as many unvaccinated migrants continue to pour into the Big Apple. NYC whooping cough cases ...
Pertussis was well known throughout Europe by the middle of the 18th century. Jules Bordet and Octave Gengou described in 1900 the finding of a new “ovoid bacillus” in the sputum of a 6-month-old infant with whooping cough. They were also the first to cultivate Bordetella pertussis at the Pasteur Institute in Brussels in 1906. [9]
DTaP (also DTP and TDaP) is a combination vaccine against diphtheria, tetanus, and pertussis, in which the pertussis component is acellular. [25] This is in contrast to whole-cell, inactivated DTP (or DTwP). [9] The acellular vaccine uses selected antigens of the pertussis pathogen to induce immunity. [17]